NPM1 Mutations in Acute Myeloid Leukemia

by Kamran Mirza MBBS PhD FCAP
April 6, 2026

If your bone marrow or molecular test results mention an NPM1 mutation, this refers to a change in the NPM1 gene, which is found in approximately 30% of adults with acute myeloid leukemia (AML) — making it the single most commonly mutated gene in this disease. An NPM1 mutation carries two equally important implications: it is one of the most favorable prognostic findings in AML when certain other mutations are absent, and it provides an exceptionally reliable marker for tracking tiny amounts of remaining leukemia after treatment — a process called minimal residual disease (MRD) monitoring. For many patients, the NPM1 result is the molecular finding their medical team will follow most closely throughout their entire treatment journey, from diagnosis through remission and beyond.

What the test looks for

The NPM1 gene encodes a protein called nucleophosmin. In a healthy cell, nucleophosmin lives mainly inside the nucleus — the compartment at the center of the cell that houses the DNA. There, it does several important jobs: it helps assemble the machinery cells use to make proteins, it assists in repairing damaged DNA, and it helps control how and when cells divide.

Crucially, nucleophosmin shuttles back and forth between the nucleus and the surrounding cell body (called the cytoplasm). It spends most of its time in the nucleus, where its work happens, and returns there after any trips out. A short sequence of amino acids — the building blocks that make up the protein — acts like a signal that keeps pulling it back in.

When the NPM1 gene is mutated, this return signal is disrupted. The mutated nucleophosmin protein cannot return to the nucleus. Instead, it gets stuck in the cytoplasm — stranded outside the compartment where it is needed. Think of a key worker who has been locked out of their office and can no longer do their job. The nucleus loses a protein it depends on, and the cell loses control over growth and division.

This mislocalization — nucleophosmin ending up in the wrong place — is the defining feature of NPM1-mutated AML. It is so consistent that pathologists can detect it not just by reading the genetic code, but also by staining cells with a dye that shows where the NPM1 protein sits. In an NPM1-mutated leukemia cell, the stain lights up the cytoplasm rather than the nucleus — a pattern visible directly under the microscope.

Nearly all NPM1 mutations in AML involve a small insertion of extra genetic material into a specific region of the gene — a four-letter stretch inserted into exon 12. While dozens of variants of this insertion exist, they all produce the same result: a protein that cannot return to the nucleus. The most common variant is called NPM1 mutation type A, which accounts for approximately 75–80% of all NPM1 mutations in AML.

Why is the test done

NPM1 testing is performed as part of the standard molecular workup for all newly diagnosed AML. The result serves three purposes: classifying the AML subtype and assessing prognosis, identifying patients who may benefit from specific treatments, and establishing the molecular marker used for MRD monitoring throughout treatment.

NPM1 mutation status is one of the most powerful prognostic markers in AML. In patients with a normal chromosome picture — meaning no large chromosomal rearrangements are present — an NPM1 mutation in the absence of a high-burden FLT3-ITD mutation is classified as a favorable-risk finding by the European LeukemiaNet (ELN) guidelines, the international standard for risk-stratifying AML. Patients in this category respond well to standard chemotherapy, achieve remission at high rates, and have substantially better long-term survival than patients with many other AML molecular profiles.

The result also determines which molecular marker will be used for all subsequent MRD testing — tracking how deeply the leukemia has responded to treatment, and detecting any early signs of return.

How the test is performed

NPM1 mutation testing is performed on a bone marrow sample or on a blood sample when large numbers of leukemia blasts are circulating in the blood at the time of diagnosis.

Next-generation sequencing (NGS) — a technology that reads the genetic code across many genes at once — is the primary method used at diagnosis. NGS detects NPM1 mutations alongside FLT3, IDH1, IDH2, TP53, and dozens of other clinically relevant genes in a single test.

For MRD monitoring after treatment, a highly sensitive test called PCR (polymerase chain reaction) is used instead. PCR can detect NPM1 mutation sequences at extremely low levels, as few as one leukemia cell among 100,000 to 1,000,000 normal cells. This extraordinary sensitivity is what makes NPM1 such a valuable MRD marker: it can find traces of remaining leukemia that are far too small to be detected by microscopy or standard blood tests. PCR-based NPM1 MRD testing can be performed on either a bone marrow or blood sample, and many centers now prefer blood for serial monitoring because it avoids repeated bone marrow procedures.

How results are reported

At diagnosis

The initial NPM1 result is reported as mutation detected or not detected. When a mutation is found, the report will identify the specific variant — for example, NPM1 exon 12 insertion, type A — and include the variant allele frequency (VAF): the proportion of tested cells carrying the mutation. A high VAF at diagnosis indicates that most leukemia cells carry the NPM1 mutation, which is typical.

During and after treatment: MRD results

Once treatment begins, NPM1 MRD results are reported as copies of NPM1 mutation per a fixed number of normal cells — for example, “NPM1 mutation: 50 copies per 100,000 ABL1 copies” — or as a ratio relative to a reference gene. Results may also be expressed as log reductions from the baseline level at diagnosis.

The key categories used in clinical practice are:

MRD negative. No NPM1 mutation copies are detected in the sample. This is the deepest measurable response and is the target of treatment. Achieving MRD negativity — particularly in the bone marrow after completing induction chemotherapy — is strongly associated with long-term remission and reduced risk of relapse.
MRD positive. NPM1 mutation copies are detectable, even at very low levels. A persistently positive MRD result after chemotherapy, or a result that fails to fall to a very low level, is associated with a higher risk of relapse. The specific level and trajectory — whether it is falling, stable, or rising — matters as much as the number itself.
MRD rising. An increase in detectable NPM1 copies across two or more consecutive tests, after a period of negativity or very low positivity, is called molecular relapse. This is often detectable weeks to months before relapse becomes apparent in the blood count or bone marrow, giving an important early warning that allows treatment decisions to be made before the disease returns in force.

What the result means

NPM1 mutation detected — prognosis

An NPM1 mutation is one of the most favorable molecular findings in AML — but its prognostic significance depends critically on the other mutations present alongside it.

When NPM1 is mutated, and the leukemia does not also carry a high-burden FLT3-ITD mutation, the overall risk classification is favorable. In large clinical trials, patients in this category achieve complete remission rates of approximately 80–90% with standard induction chemotherapy, and long-term survival rates are substantially better than in patients with intermediate or high-risk AML. Many patients in this category are cured with chemotherapy alone, without needing a stem cell transplant.

When NPM1 is mutated alongside a high-burden FLT3-ITD mutation — meaning the FLT3 allelic ratio is 0.5 or above — the favorable prognosis conferred by NPM1 is substantially reduced. The combination pushes the risk classification into the intermediate category, and stem cell transplantation in first remission is more likely to be recommended. The interaction between NPM1 and FLT3 is one of the most important co-mutation combinations in all of AML, which is why both are always tested together.

When NPM1 is mutated alongside a low-burden FLT3-ITD mutation — allelic ratio below 0.5 — or alongside other mutations such as DNMT3A or IDH1/IDH2, the risk classification depends on the full molecular picture. Your hematologist will explain how all the findings together determine your risk category under the ELN guidelines.

NPM1 mutation detected — what it means for treatment

For patients who are fit for intensive chemotherapy, standard induction chemotherapy — typically the combination of cytarabine and an anthracycline such as daunorubicin — remains the backbone of initial treatment for NPM1-mutated AML. There is currently no approved drug that specifically targets the NPM1 mutation, as FLT3 inhibitors target FLT3 and IDH inhibitors target IDH1/IDH2.

However, the combination of venetoclax and azacitidine — a lower-intensity regimen used for older or less fit patients who cannot tolerate intensive chemotherapy — has shown particularly strong activity in NPM1-mutated AML. In the VIALE-A trial, patients with NPM1-mutated AML who received venetoclax plus azacitidine had a complete response rate of approximately 71%, substantially higher than in patients without an NPM1 mutation on the same regimen. This makes venetoclax plus azacitidine an especially well-supported option for older adults with NPM1-mutated AML.

An emerging class of drugs called menin inhibitors — including revumenib (Revuforj) and ziftomenib — has shown activity specifically in NPM1-mutated AML. The connection is biological: NPM1 mutations partly dysregulate a group of genes called HOX genes, and the menin protein plays a key role in this dysregulation. Blocking menin interferes with the mechanism that NPM1-mutated leukemia cells depend on to survive. Revumenib received FDA approval in 2023 for relapsed or treatment-resistant AML with certain genetic features, including NPM1 mutations, and clinical trials are evaluating its use in newly diagnosed disease. This represents an important development in the treatment of NPM1-mutated AML, though it is not yet a first-line standard treatment in most settings. Your hematologist will advise whether a menin inhibitor is relevant to your situation.

NPM1 mutation detected — stem cell transplantation

For patients with favorable-risk NPM1-mutated AML — those without a high-burden FLT3-ITD mutation and whose leukemia achieves MRD negativity after chemotherapy — stem cell transplantation in first remission is generally not recommended. Chemotherapy alone, followed by careful MRD monitoring, is considered sufficient in this group, and the risks of transplantation outweigh the benefits when the disease has responded so well. This is an important message for patients: an NPM1 mutation with a good MRD response may mean that a transplant is not part of the plan.

For patients with intermediate-risk NPM1-mutated AML — for example, those with a co-occurring high-burden FLT3-ITD mutation, or those whose MRD does not become negative after induction chemotherapy — stem cell transplantation is more likely to be recommended. MRD status after treatment is one of the primary factors used to make this decision.

NPM1 not detected

A negative NPM1 result means this mutation was not found in the leukemia cells tested. The full set of molecular findings will guide risk classification and treatment decisions — FLT3, IDH1/IDH2, CEBPA, TP53, and the chromosome picture. A negative NPM1 result also means that NPM1-based PCR cannot be used for MRD monitoring, and alternative MRD approaches — such as flow cytometry or sequencing — will be used instead.

NPM1 MRD monitoring: what to expect

For patients with NPM1-mutated AML, molecular MRD monitoring is one of the most important ongoing aspects of care after treatment. Understanding how it works and what the results mean makes it easier to engage with your medical team throughout follow-up.

After completing induction chemotherapy — the first intensive round of treatment — a bone marrow test is performed to assess response. In addition to the standard microscopy examination, NPM1 PCR MRD testing is performed. Achieving MRD negativity at this point is strongly associated with long-term remission. Failure to achieve MRD negativity — even when the bone marrow looks normal under the microscope — is associated with a higher risk of relapse and may prompt consideration of more intensive consolidation treatment or stem cell transplantation.

After completing consolidation chemotherapy and entering remission, NPM1 MRD monitoring continues at regular intervals — typically every one to three months in the first year, then less frequently thereafter. These tests are most often performed on blood samples, allowing monitoring without bone marrow procedures at every visit.

A rising NPM1 MRD level — particularly one confirmed on two consecutive tests — is a signal that leukemia cells are beginning to return, even if blood counts and bone marrow examination still look normal. This molecular relapse often precedes clinical relapse by weeks to months, giving the treatment team time to respond early. What happens next depends on the rate of rise, the level reached, and your overall situation — your hematologist will explain the options at that point, which may include a change of treatment, enrolment in a clinical trial, or consideration of transplantation.

Not all NPM1 MRD rises lead to full relapse, and a single elevated result does not necessarily mean the disease is coming back. Your hematologist will interpret each result in context, looking at the trend over time rather than any individual number in isolation.

NPM1 mutations are not inherited

NPM1 mutations in AML are almost always somatic — they develop in a blood-forming cell during a person’s lifetime and are not present in any other cells in the body. They are not inherited and cannot be passed to children. There is no hereditary condition associated with somatic NPM1 mutations in AML. A positive NPM1 result does not have implications for the patient’s biological relatives.

What happens next

For most patients with newly diagnosed NPM1-mutated AML who are fit for intensive treatment, induction chemotherapy begins quickly — typically within days of diagnosis. The NPM1 mutation result, together with FLT3 status, determines the risk category and shapes decisions about the intensity of post-remission treatment and whether a stem cell transplant will be needed.

For older or less fit patients, venetoclax plus azacitidine is a well-supported treatment approach with particularly strong activity in NPM1-mutated AML. Your hematologist will recommend the regimen best suited to your overall health.

Once treatment begins, regular NPM1 PCR MRD monitoring will become part of your routine follow-up. Your hematologist will explain how often testing will happen, what each result means, and what level of response is being targeted. Achieving and sustaining MRD negativity is the goal, and the monitoring schedule will be adjusted as your results evolve.

If your leukemia has relapsed and carries an NPM1 mutation, your hematologist will discuss options including menin inhibitor therapy, salvage chemotherapy, venetoclax-based regimens, and clinical trials. Stem cell transplantation may also be discussed if it was not part of the first treatment plan.

Questions to ask your doctor

Do I have an NPM1 mutation, and which specific variant is it?
Do I also have a FLT3-ITD mutation, and if so, what is the allelic ratio? How do the NPM1 and FLT3 results together determine my risk category?
Based on my risk category, is stem cell transplantation being planned — or is chemotherapy alone the recommended approach?
Will NPM1 PCR be used to monitor MRD throughout my treatment, and how often will testing happen?
What NPM1 MRD level are you targeting after induction chemotherapy, and what would a persistently positive result mean for my treatment plan?
If my MRD level rises during follow-up, at what point would that prompt a change in management?
Is venetoclax-based treatment being considered for me, and what is the evidence for it in NPM1-mutated AML?
Are there clinical trials involving menin inhibitors or other treatments for NPM1-mutated AML that I should be aware of?